Fact based stock research
Chongqing Lummy Pharmaceutical (SZSE:300006)

CNE100000H10



Due to the geopolitical instabilities, research on companies located in authoritarian regimes has been discontinued. Research at Obermatt is limited to companies in democracies as measured by The Economist Intelligence Unit Democracy Index.



Chongqing Lummy Pharmaceutical stock research in summary

cqlummy.com


There is no stock research analysis by the purely financial fact-based Obermatt method for: Chongqing Lummy Pharmaceutical (SZSE:300006), Pharmaceuticals, China. Contact us if you would like research on this stock.


Latest Obermatt Ranks


Country China
Industry Pharmaceuticals
Index
Size class Small

August 23, 2018. Stock data may be delayed. Login to get the most recent research.

Research History: Chongqing Lummy Pharmaceutical

RESEARCH HISTORY 2019 2020 2021 2022
VALUE
VALUE
GROWTH
GROWTH
SAFETY
SAFETY
COMBINED
COMBINED

Last update of Combined Rank: 23-Aug-2018. Financial reporting date used for calculating ranks: 31-Mar-2017. Stock research history is based on the Obermatt Method. The higher the rank, the better Chongqing Lummy Pharmaceutical is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2019 2020 2021 2022
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)
DIVIDEND YIELD
DIVIDEND YIELD
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE

Last update of Value Rank: 23-Aug-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Chongqing Lummy Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2019 2020 2021 2022
REVENUE GROWTH
REVENUE GROWTH
PROFIT GROWTH
PROFIT GROWTH
STOCK RETURNS
STOCK RETURNS
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH

Last update of Growth Rank: 31-Mar-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Chongqing Lummy Pharmaceutical.


Safety Metrics in Detail

SAFETY METRICS 2019 2020 2021 2022
LEVERAGE
LEVERAGE
REFINANCING
REFINANCING
LIQUIDITY
LIQUIDITY
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY

Last update of Safety Rank: 23-Aug-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Chongqing Lummy Pharmaceutical and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Chongqing Lummy Pharmaceutical from August 23, 2018.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.